{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:59:43Z","timestamp":1761947983926,"version":"3.40.4"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/spv.0000000000000076","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T13:24:15Z","timestamp":1403270655000},"page":"185-202","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological Treatment of Urinary Incontinence"],"prefix":"10.1097","volume":"20","author":[{"given":"Lucio M.A.","family":"Cipullo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosimo","family":"Cosimato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Di Spiezio Sardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Troisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"2","key":"R1-1-20210207","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ajog.2006.01.023","article-title":"Urinary incontinence and age at the first and last delivery: the Norwegian HUNTEPINCONT study.","volume":"195","author":"Rortveit","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"R2-1-20210207","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ogc.2009.08.001","article-title":"Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.","volume":"36","author":"Saks","year":"2009","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"1","key":"R3-1-20210207","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9378(96)70243-0","article-title":"The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction.","volume":"175","author":"Bump","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"R4-1-20210207","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2009.01.007","article-title":"A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women.","volume":"55","author":"Wennberg","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"R5-1-20210207","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2010.11.021","article-title":"EAU guidelines on urinary incontinence.","volume":"59","author":"Thuroff","year":"2011","journal-title":"Eur Urol"},{"issue":"4-6","key":"R8-1-20210207","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00210-007-0209-z","article-title":"Therapeutic receptor targets for lower urinary tract dysfunction.","volume":"377","author":"Yoshimura","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"R9-1-20210207","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/nau.21102","article-title":"Researching bladder afferentsdetermining the effects of (3)-adrenergic receptor agonists and botulinum toxin type-A.","volume":"30","author":"Kanai","year":"2011","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"R10-1-20210207","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrn2401","article-title":"The neural control of micturition.","volume":"9","author":"Fowler","year":"2008","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"R12-1-20210207","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/sj.bjp.0701048","article-title":"Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo.","volume":"120","author":"Hegde","year":"1997","journal-title":"Br J Pharmacol"},{"issue":"5-6","key":"R13-1-20210207","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2680.2001.00231.x","article-title":"The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro.","volume":"21","author":"Chess-Williams","year":"2001","journal-title":"J Auton Pharmacol"},{"issue":"5","key":"R14-1-20210207","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bjp.0704781","article-title":"M3 muscarinic receptors mediate contraction of human urinary bladder.","volume":"136","author":"Fetscher","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"3","key":"R16-1-20210207","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/jpet.103.063735","article-title":"Signal transduction underlying carbachol-induced contraction of human urinary bladder.","volume":"309","author":"Schneider","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"4-6","key":"R17-1-20210207","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00210-008-0274-y","article-title":"Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium.","volume":"377","author":"Otsuka","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"R18-1-20210207","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/nau.20965","article-title":"Urothelial beta-3 adrenergic receptors in the rat bladder.","volume":"30","author":"Kullmann","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R19-1-20210207","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.ju.0000067621.62736.7c","article-title":"A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.","volume":"170","author":"Nomiya","year":"2003","journal-title":"J Urol"},{"issue":"1","key":"R20-1-20210207","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/S1677-55382009000100012","article-title":"Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder.","volume":"35","author":"Tyagi","year":"2009","journal-title":"Int Braz J Urol"},{"issue":"3","key":"R22-1-20210207","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.bjp.0702358","article-title":"Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle.","volume":"126","author":"Igawa","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"3","key":"R23-1-20210207","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","article-title":"Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods.","volume":"288","author":"Takeda","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-1-20210207","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0090-4295(01)01635-1","article-title":"Beta3-adrenoceptors in human detrusor muscle.","volume":"59","author":"Yamaguchi","year":"2002","journal-title":"Urology"},{"issue":"6","key":"R26-1-20210207","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1464-410X.2006.06564.x","article-title":"The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder.","volume":"98","author":"Biers","year":"2006","journal-title":"BJU Int"},{"issue":"4","key":"R27-1-20210207","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.urology.2007.01.059","article-title":"Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines.","volume":"69","author":"Badawi","year":"2007","journal-title":"Urology"},{"issue":"1","key":"R28-1-20210207","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/jpet.108.138651","article-title":"Effects of the beta 3-adrenergic receptor agonist disodium 5-(2R)-2-(2R)-2-(3-chlorophenyl)-2-hydroxyethylaminopropyl-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats.","volume":"326","author":"Leon","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"R29-1-20210207","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/physrev.00038.2003","article-title":"Urinary bladder contraction and relaxation: physiology and pathophysiology.","volume":"84","author":"Andersson","year":"2004","journal-title":"Physiol Rev"},{"key":"R32-1-20210207","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00498259209053145","article-title":"Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.","volume":"22","author":"Hughes","year":"1992","journal-title":"Xenobiotica"},{"issue":"6","key":"R34-1-20210207","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"issue":"4","key":"R35-1-20210207","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00345-004-0455-3","article-title":"Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.","volume":"22","author":"Homma","year":"2004","journal-title":"World J Urol"},{"key":"R36-1-20210207","first-page":"CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults.","volume":"1","author":"Madhuvrata","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"R37-1-20210207","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00003495-200464080-00011","article-title":"Oxybutynin extended-release: a review of its use in the management of overactive bladder.","volume":"64","author":"Siddiqui","year":"2004","journal-title":"Drugs"},{"issue":"4","key":"R38-1-20210207","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.maturitas.2009.12.022","article-title":"New drug treatments for urinary incontinence.","volume":"65","author":"Robinson","year":"2010","journal-title":"Maturitas"},{"key":"R39-1-20210207","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"issue":"5","key":"R40-1-20210207","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5414\/CPP38223","article-title":"Trospium chloride: an effective option for medical treatment of bladder overactivity.","volume":"38","author":"Fusgen","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"R42-1-20210207","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.juro.2010.01.012","article-title":"Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.","volume":"183","author":"Herschorn","year":"2010","journal-title":"J Urol"},{"issue":"8","key":"R44-1-20210207","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1532-5415.2009.02369.x","article-title":"How to manage overactive bladder in elderly individuals with dementia Combined use of donepezil, a central acetylcholinesterase inhibitor and propiverine, a peripheral muscarine receptor antagonist.","volume":"57","author":"Sakakibara","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"R45-1-20210207","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"issue":"13-14","key":"R46-1-20210207","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","article-title":"Tolterodinea new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.","volume":"60","author":"Nilvebrant","year":"1997","journal-title":"Life Sci"},{"issue":"10","key":"R47-1-20210207","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1345\/aph.18427","article-title":"Tolterodine use for symptoms of overactive bladder.","volume":"33","author":"Ruscin","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"2-3","key":"R48-1-20210207","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","article-title":"Tolterodinea new bladder-selective antimuscarinic agent.","volume":"327","author":"Nilvebrant","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"R49-1-20210207","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urology.2007.11.008","article-title":"Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo controlled interventional study.","volume":"71","author":"Dmochowski","year":"2008","journal-title":"Urology"},{"issue":"2","key":"R50-1-20210207","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1524-4733.2009.00652.x","article-title":"Extended-release trospium chloride improves quality of life in overactive bladder.","volume":"13","author":"Dmochowski","year":"2010","journal-title":"Value Health"},{"issue":"4","key":"R51-1-20210207","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","article-title":"Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia.","volume":"75","author":"Madersbacher","year":"1995","journal-title":"Br J Urol"},{"issue":"Suppl 2","key":"R52-1-20210207","first-page":"12","article-title":"Trospium chloride versus oxybutynin in the treatment of bladder neurological disorders: a double blind randomized clinical trial Abstract.","volume":"80","author":"Osca","year":"1997","journal-title":"Br J Urol"},{"issue":"6","key":"R53-1-20210207","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.","volume":"20","author":"Halaska","year":"2003","journal-title":"World J Urol"},{"issue":"11","key":"R54-1-20210207","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.clinthera.2009.11.005","article-title":"Trospium chloride and oxybutynin hydrochloride in a German study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.","volume":"31","author":"Zellner","year":"2009","journal-title":"Clin Ther"},{"issue":"13-14","key":"R56-1-20210207","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0024-3205(97)00047-7","article-title":"Discovery and development of selective M3 antagonists for clinical use.","volume":"60","author":"Alabaster","year":"1997","journal-title":"Life Sci"},{"issue":"4","key":"R57-1-20210207","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"R58-1-20210207","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1007\/PL00014139","article-title":"Medical treatment and medical side effects in urinary incontinence in the elderly.","volume":"16","author":"Thuroff","year":"1998","journal-title":"World J Urol"},{"key":"R59-1-20210207","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.2174\/092986709789712835","article-title":"The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.","volume":"16","author":"Malhotra","year":"2009","journal-title":"Curr Med Chem"},{"key":"R60-1-20210207","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1464-410x.2001.02134.x","article-title":"Systemic effects of intravesical atropine sulphate.","volume":"87","author":"Enskat","year":"2001","journal-title":"BJU Int"},{"issue":"1","key":"R61-1-20210207","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)36029-9","article-title":"Urodynamic effects of intravesical instillation of atropine and phentolamine in patients with detrusor hyperactivity.","volume":"149","author":"Ekstrom","year":"1993","journal-title":"J Urol"},{"key":"R62-1-20210207","first-page":"36","article-title":"Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study.","volume":"33","author":"Glickman","year":"1995","journal-title":"Paraplegia"},{"issue":"6","key":"R63-1-20210207","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jnnp.65.6.957","article-title":"Intravesical atropine suppression of detrusor hyperreflexia in multiple sclerosis.","volume":"65","author":"Deaney","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"R64-1-20210207","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.juro.2006.08.099","article-title":"Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.","volume":"177","author":"Fader","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"R65-1-20210207","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/cpt1972132212","article-title":"On the metabolism of propantheline in man.","volume":"13","author":"Beermann","year":"1972","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"R66-1-20210207","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1464-410X.2007.07162.x","article-title":"A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.","volume":"100","author":"Robinson","year":"2007","journal-title":"BJU Int"},{"issue":"4","key":"R68-1-20210207","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.juro.2007.11.060","article-title":"Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.","volume":"179","author":"Low","year":"2008","journal-title":"J Urol"},{"issue":"1","key":"R69-1-20210207","first-page":"117","article-title":"Prazosin: a neglected cause of genuine stress incontinence.","volume":"79","author":"Dwyer","year":"1992","journal-title":"Obstet Gynecol"},{"issue":"1","key":"R70-1-20210207","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3346\/jkms.2010.25.1.117","article-title":"Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: an 8-week prospective study.","volume":"25","author":"Lee","year":"2010","journal-title":"J Korean Med Sci"},{"issue":"2","key":"R74-1-20210207","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a (3)-adrenoceptor agonist, in overactive bladder.","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"R76-1-20210207","first-page":"239","article-title":"Clinical proof of concept study (Blossom) shows novel 3 adrenoreceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder.","volume":"7","author":"Chapple","year":"2008","journal-title":"Eur Urol Suppl"},{"issue":"2","key":"R77-1-20210207","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a (3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"R78-1-20210207","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/TCRM.S33052","article-title":"New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.","volume":"9","author":"Andersson","year":"2013","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"R79-1-20210207","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-013-0086-3","article-title":"Mirabegron: a review of its use in patients with overactive bladder syndrome.","volume":"73","author":"Sanford","year":"2013","journal-title":"Drugs"},{"issue":"4","key":"R81-1-20210207","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"issue":"1","key":"R85-1-20210207","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0022-5347(01)63020-9","article-title":"The incidence of a positive ice water test in bladder outlet obstructed patients: evidence for bladder neural plasticity.","volume":"160","author":"Chai","year":"1998","journal-title":"J Urol"},{"issue":"2","key":"R86-1-20210207","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0022-5347(05)64683-6","article-title":"The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input.","volume":"168","author":"Silva","year":"2002","journal-title":"J Urol"},{"issue":"5","key":"R87-1-20210207","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/003655998750015287","article-title":"Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases.","volume":"32","author":"Lazzeri","year":"1998","journal-title":"Scand J Urol Nephrol"},{"key":"R88-1-20210207","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0022-3565(25)10548-X","article-title":"Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetised female cat.","volume":"274","author":"Thor","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"R90-1-20210207","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2125.2012.04389.x","article-title":"Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice.","volume":"75","author":"Michel","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"R91-1-20210207","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1067\/mob.2002.124840","article-title":"Duloxetine versus placebo in the treatment of stress urinary incontinence.","volume":"187","author":"Norton","year":"2002","journal-title":"Am J Obstet Gynaecol"},{"issue":"2","key":"R92-1-20210207","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/0253-7613.77357","article-title":"Evaluation of efficacy of duloxetine in stress urinary incontinence in women.","volume":"43","author":"Deepak","year":"2011","journal-title":"Indian J Pharmacol"},{"issue":"3","key":"R93-1-20210207","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1464-410X.2004.04607.x","article-title":"Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial.","volume":"93","author":"Millard","year":"2004","journal-title":"BJU Int"},{"issue":"8","key":"R94-1-20210207","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00192-006-0256-x","article-title":"Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence.","volume":"18","author":"Castro-Diaz","year":"2007","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"Suppl 1","key":"R95-1-20210207","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1471-0528.2006.00880.x","article-title":"Safety and tolerability of duloxetine in women with stress urinary incontinence.","volume":"113","author":"Oelke","year":"2006","journal-title":"BJOG"},{"key":"R96-1-20210207","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/15.5.299","article-title":"Double-blind study of imipramine and placebo for incontinence due to bladder instability.","volume":"15","author":"Castleden","year":"1986","journal-title":"Age Ageing"},{"key":"R97-1-20210207","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-5347(17)60942-X","article-title":"Comparison of action of imipramine (tofranil) and propantheline (probanthine) on detrusor contraction.","volume":"107","author":"Diokno Ac, Hyndman","year":"1972","journal-title":"J Urol"},{"issue":"2","key":"R98-1-20210207","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s002400100175","article-title":"Clinical options for imipramine in the management of urinary incontinence.","volume":"29","author":"Hunsballe","year":"2001","journal-title":"Urol Res"},{"issue":"3","key":"R99-1-20210207","first-page":"CD002117","article-title":"Tricyclic and related drugs for nocturnal enuresis in children.","author":"Glazener","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"R101-1-20210207","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1185\/030079903125002126","article-title":"Pharmacological agents used for the treatment of stress urinary incontinence in women.","volume":"19","author":"Viktrup","year":"2003","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"R102-1-20210207","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(17)59648-2","article-title":"The urethral continence zone and its relation to stress incontinence.","volume":"112","author":"Gleason","year":"1974","journal-title":"J Urol"},{"issue":"5","key":"R103-1-20210207","first-page":"351","article-title":"Beta adrenoceptor blockade in the treatment of female urinary stress incontinence.","volume":"90","author":"Kaisary","year":"1984","journal-title":"J Urol (Paris)"},{"issue":"3","key":"R104-1-20210207","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0031-6997(25)00442-9","article-title":"Pharmacology of lower urinary tract smooth muscles and penile erectile tissues.","volume":"45","author":"Andersson","year":"1993","journal-title":"Pharmacol Rev"},{"issue":"1","key":"R105-1-20210207","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1748-1716.1980.tb06569.x","article-title":"Functional and metabolic effects of terbutaline and propranolol in fast- and slow-contracting skeletal muscle in vitro.","volume":"109","author":"Fellenius","year":"1980","journal-title":"Acta Physiol Scand"},{"issue":"4","key":"R106-1-20210207","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00192-008-0761-1","article-title":"Pharmacotherapy of urinary incontinence.","volume":"20","author":"Athanasopoulos","year":"2009","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"}],"container-title":["Female Pelvic Medicine & Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPV.0000000000000076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T12:09:48Z","timestamp":1746274188000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01436319-201407000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/spv.0000000000000076","relation":{},"ISSN":["2151-8378"],"issn-type":[{"type":"print","value":"2151-8378"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}